Edition:
India

Genfit SA (GNFT.PA)

GNFT.PA on Paris Stock Exchange

25.10EUR
3:39pm IST
Change (% chg)

€0.00 (+0.00%)
Prev Close
€25.10
Open
€25.20
Day's High
€25.32
Day's Low
€25.02
Volume
28,289
Avg. Vol
191,106
52-wk High
€35.65
52-wk Low
€20.11

Latest Key Developments (Source: Significant Developments)

Genfit announces positive outcome of DSMB safety review
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - GENFIT SA ::REG-GENFIT: POSITIVE OUTCOME FROM THE 18-MONTH PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR.‍SAFETY DATA REVIEWED BY DSMB WHICH RECOMMENDED CONTINUATION OF TRIAL WITHOUT ANY MODIFICATIONS​.‍POSITIVE OUTCOME OF REVIEW ALLOWS GENFIT TO ACTIVELY PURSUE ITS EFFORT IN ENROLLING PATIENTS AND CONTINUATION OF RESOLVE-IT TRIAL​.‍POSITIVE OUTCOME CONFIRMS GOOD SAFETY PROFILE OF ELAFIBRANOR​.  Full Article

Genfit completes offering of convertible bonds due 2022 for 180 million euros
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - GENFIT SA ::REG-GENFIT COMPLETES A €180 MILLION OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022.‍OFFERING WAS MULTIPLE TIMES OVERSCRIBED, INITIAL AMOUNT OF OFFERING WAS INCREASED FROM EUR 150 MILLION TO EUR 180 MILLION​.NOMINAL UNIT VALUE OF THE OCEANES WAS SET AT €29.60, REPRESENTING A CONVERSION/EXCHANGE PREMIUM OF 30% TO CO’S REFERENCE SHARE PRICE‍​.‍OCEANES BEAR INTEREST AT AN ANNUAL NOMINAL RATE OF 3.50% PAYABLE SEMI-ANNUALLY IN ARREARS ON APRIL 16, AND OCT 16 OF EACH YEAR​.  Full Article

Genfit completes convertible bonds offering for amount of 180 million euros
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - GENFIT SA ::REG-GENFIT ANNOUNCES THE SUCCESS OF ITS OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022 FOR AN AMOUNT OF €180 MILLION.‍INITIAL AMOUNT OF EUR 150 MILLION HAS BEEN INCREASED TO EUR 180 MILLION IN ACCORDANCE WITH CORPORATE AUTHORIZATIONS OF COMPANY​.  Full Article

Genfit launches an offering of conbertible bonds for around 150 million euros
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - GENFIT SA ::GENFIT LAUNCHES AN OFFERING OF BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES ("OCEANES") DUE 2022 FOR AN AMOUNT OF APPROXIMATELY €150 MILLION.‍OCEANES WILL BEAR INTEREST AT AN ANNUAL NOMINAL RATE COMPRISED BETWEEN 3.00% AND 3.50% PAYABLE SEMI-ANNUALLY​.‍NOMINAL UNIT VALUE OF OCEANES WILL BE SET AT A CONVERSION/EXCHANGE PREMIUM OF BETWEEN 30% AND 35% TO GENFIT'S REFERENCE SHARE PRICE​.BONDS TO BE REDEEMED AT PAR ON OCT 16, 2022.‍​.  Full Article

Genfit reports‍ nine months revenues at 91 thousand euros
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - GENFIT SA : :‍CASH AND CASH EQUIVALENTS OF EUR 113.8 MILLION AT SEPTEMBER 30, 2017​.‍REVENUES FOR FIRST NINE MONTHS OF 2017 OF EUR 91 THOUSAND​.  Full Article

Genfit successfully raises 33.9 million euros in private placement
Thursday, 6 Oct 2016 

Genfit SA : Genfit raises 33.9 million euros in private placement . Has placed 1,695,000 new ordinary shares at a price of 20.00 euros per share . Offering represents 6.4 pct of pre-transaction share capital . This Private Placement is the first step of a c. EUR 75-80 million fundraising .If all of the Company's programs are implemented at the pace currently expected by the Company, the proceeds of the global fundraising, together with its cash on hand, should allow the Company to finance its development until late 2018-early 2019.  Full Article

Genfit launches capital increase through private placement
Wednesday, 5 Oct 2016 

Genfit SA : Genfit launches a share capital increase through private placement . Company targets raising around 30 million euros ($33.6 million) through private placement .Private placement is first step of around 75-80 million euros fundraising.  Full Article

Genfit H1 net loss widens to 12.7 million euros
Monday, 26 Sep 2016 

Genfit SA : H1 revenue 3.6 million euros ($4.06 million) versus 2.4 million euros year ago . H1 net loss 12.7 million euros versus loss of 8.9 million euros year ago .H1 operating loss of 12.8 million euros versus loss of 9.1 million euros year ago.  Full Article

Genfit to begin Elafibranor clinical program in PBC
Thursday, 31 Mar 2016 

Genfit SA:Intends to begin a Phase 2 clinical trial of Elafibranor in treatment of PBC before end of 2016.Also announced its intention to launch new trials in NASH for pediatric as well as cirrhosis subpopulations.  Full Article

Genfit announces enrollment of first patient in RESOLVE-IT
Thursday, 10 Mar 2016 

Genfit SA:Announces enrollment of first patient in RESOLVE-IT, the pivotal Phase 3 clinical trial of Elafibranor in NASH.  Full Article

BRIEF-Genfit announces positive outcome of DSMB safety review

* REG-GENFIT: POSITIVE OUTCOME FROM THE 18-MONTH PRE-PLANNED SAFETY REVIEW BY THE DSMB, IN RESOLVE-IT PHASE 3 CLINICAL TRIAL WITH ELAFIBRANOR